DCb (docetaxel/carboplatin) versus EC followed by D (epirubicin/cyclophosphamide followed by docetaxe)
20170512
Phase 2 small_molecule completed
Quick answer
DCb (docetaxel/carboplatin) versus EC followed by D (epirubicin/cyclophosphamide followed by docetaxe) for Triple-Negative Breast Cancer is a Phase 2 program (small_molecule) at First Tracks Biotherapeutics with 1 ClinicalTrials.gov record(s).
Program details
- Company
- First Tracks Biotherapeutics
- Indication
- Triple-Negative Breast Cancer
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- completed